0001104659-17-033537.txt : 20170517 0001104659-17-033537.hdr.sgml : 20170517 20170517190118 ACCESSION NUMBER: 0001104659-17-033537 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170216 FILED AS OF DATE: 20170517 DATE AS OF CHANGE: 20170517 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics AG CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: C4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 BUSINESS PHONE: 43 (0)1 740 93-0 MAIL ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Talbot George Harrison CENTRAL INDEX KEY: 0001554194 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 17853143 MAIL ADDRESS: STREET 1: C/O DURATA THERAPEUTICS, INC. STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR CITY: MORRISTOWN STATE: NJ ZIP: 07960 4 1 a4.xml 4 X0306 4 2017-02-16 0 0001641640 Nabriva Therapeutics AG NBRV 0001554194 Talbot George Harrison 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 1 0 0 0 Common Shares 2017-02-16 4 M 0 502 A 3351 D Common Shares 2017-02-16 4 M 0 155 A 3506 D Common Shares 2017-02-16 4 M 0 578 A 4084 D Common Shares 2017-05-15 4 S 0 50 101.50 D 4034 D Common Shares 2017-05-16 4 S 0 50 102.268 D 3984 D Common Shares 2017-05-16 4 S 0 100 103.00 D 3884 D Stock Option 2017-02-16 4 M 0 502 0 D 2017-09-27 Common Shares 502 0 D Stock Option 2017-02-16 4 M 0 155 0 D 2017-09-27 Common Shares 155 0 D Stock Option 2017-02-16 4 M 0 578 0 D 2017-09-27 Common Shares 578 135 D This transaction is being reported late due to an administrative oversight. The exercise price was Euro 6.72 per common share. The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares. The price of $101.50 per common share was derived from the sale price on May 15, 2017, of $10.15 per ADS, multiplied by ten. The price of $102.268 per common share was derived from the sale price on May 16, 2017, of $10.2268 per ADS, multiplied by ten. The price of $103.00 per common share was derived from the sale price on May 16, 2017, of $10.30 per ADS, multiplied by ten. This option was granted on June 12, 2009 and is fully vested. This option was granted on January 29, 2010 and is fully vested. This option was granted on August 31, 2014. Vesting began on August 31, 2014 and ends on September 30, 2017. Twenty-five percent (25%) of the option vested on December 31, 2014, a further twenty-five percent (25%) of the options vested on December 31, 2015, and the remaining fifty percent (50%) vests on a monthly pro-rata basis over the remaining vesting period. /s/ Gary L. Sender, by power of attorney 2017-05-17